コンテンツへスキップ
Merck
  • Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy.

Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy.

Atherosclerosis (2015-02-16)
Giuseppe Asciutto, Nuno V Dias, Andreas Edsfeldt, Ragnar Alm, Gunilla N Fredrikson, Isabel Gonçalves, Jan Nilsson
要旨

Autoimmune responses against oxidized-LDL (oxLDL) have been suggested to modulate inflammation in atherosclerosis. Previous studies showed an association between autoantibodies against the apolipoprotein B (apoB) p210 antigen and a lower risk of cardiovascular (CV) events. In the present study we investigated if autoantibodies against p210 at the time of carotid endarterectomy (CEA) predict risk for future CV events. Native (nat) and malondialdehyde (MDA)-modified apoB p210 autoantibodies (IgM-p210nat, IgG-p210nat, IgM-p210MDA and IgG-p210MDA) were analyzed by ELISA from plasma samples of 351 patients at the time they underwent CEA. The incidence of postoperative CV events was assessed using national registers. A total of 52 non-fatal and 15 fatal CV events were registered during the follow-up period (35.1 ± 16.7 months). Patients who suffered from a fatal CV event had significantly lower plasma levels of IgG-p210nat and IgG-p210MDA. Kaplan-Meier curves of event-free survival showed increased CV mortality in patients with levels of IgG-p210nat and IgG-p210MDA below the median (Log Rank 7.813, p .005 and 9.105, p .003 respectively). The association between low levels of p210 IgG and fatal post-operative CV events remained significant when adjusting for age, sex, total cholesterol, HDL cholesterol, smoking habits and hypertension in a Cox Proportional Hazard model (hazard ratios (HR) IgG-p210nat below median: HR 6.7 (95% C.I. 1.5-30.6, p .013) and IgG-p210MDA below median: HR 7.8 (95% C.I. 1.7-35.5, p .008). The present findings support the notion that autoantibodies against LDL antigens are involved in the atherosclerotic disease process and suggest that CEA patients with low levels of IgG-p210nat and IgG-p210MDA have an increased risk of post-operative CV death.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
ホスファターゼの基質, 5 mg tablets
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, suitable for enzyme immunoassay, ≥99.0% (enzymatic)
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, tablet
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
ホスファターゼの基質, powder
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, tablet
Sigma-Aldrich
ホスファターゼの基質, 40 mg tablets
Sigma-Aldrich
4-ニトロフェニルリン酸 二ナトリウム塩 六水和物, tablet
Sigma-Aldrich
ホスファターゼの基質, 100 mg capsules
Sigma-Aldrich
ホスファターゼの基質, 40 mg capsules
Sigma-Aldrich
ホスファターゼの基質, Suitable for manufacturing of diagnostic kits and reagents